Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2010-11

AUTHORS

Nicolas Widmer, Pascal Meylan, Anton Ivanyuk, Manel Aouri, Laurent A. Decosterd, Thierry Buclin

ABSTRACT

Oseltamivir is the ester-type prodrug of the neuraminidase inhibitor oseltamivir carboxylate. It has been shown to be an effective treatment for both seasonal influenza and the recent pandemic 2009 A/H1N1 influenza, reducing both the duration and severity of the illness. It is also effective when used preventively. This review aims to describe the current knowledge of the pharmacokinetic and pharmacodynamic characteristics of this agent, and to address the issue of possible therapeutic drug monitoring.According to the currently available literature, the pharmacokinetics of oseltamivir carboxylate after oral administration of oseltamivir are characterized by mean ± SD bioavailability of 79 ± 12%, apparent clearance of 25.3±7.0L/h, an elimination half-life of 7.4±2.5 hours and an apparent terminal volume of distribution of 267 ± 122 L. A maximum plasma concentration of 342±83 μg/L, a time to reach the maximum plasma concentration of 4.2 ± 1.1 hours, a trough plasma concentration of 168±32mg/L and an area under the plasma concentration-time curve from 0 to 24 hours of 6110 ± 1330 mg · h/L for a 75 mg twice-daily regimen were derived from literature data. The apparent clearance is highly correlated with renal function, hence the dosage needs to be adjusted in proportion to the glomerular filtration rate. Interpatient variability is moderate (28% in apparent clearance and 46% in the apparent central volume of distribution); there is no indication of significant erratic or limited absorption in given patient subgroups.The in vitro pharmacodynamics of oseltamivir carboxylate reveal wide variation in the concentration producing 50% inhibition of influenza A and B strains (range 0.17–44 μg/L). A formal correlation between systemic exposure to oseltamivir carboxylate and clinical antiviral activity or tolerance in influenza patients has not yet been demonstrated; thus no formal therapeutic or toxic range can be proposed.The pharmacokinetic parameters of oseltamivir carboxylate after oseltamivir administration (bioavailability, apparent clearance and the volume of distribution) are fairly predictable in healthy subjects, with little interpatient variability outside the effect of renal function in all patients and bodyweight in children. Thus oseltamivir carboxylate exposure can probably be controlled with sufficient accuracy by thorough dosage adjustment according to patient characteristics. However, there is a lack of clinical study data on naturally infected patients. In addition, the therapeutic margin of oseltamivir carboxylate is poorly defined. The usefulness of systematic therapeutic drug monitoring in patients therefore appears to be questionable; however, studies are still needed to extend the knowledge to particular subgroups of patients or dosage regimens. More... »

PAGES

741-765

References to SciGraph publications

  • 2007-03-21. Tamiflu side effects come under scrutiny in NATURE
  • 2009-06. Valganciclovir in Adult Solid Organ Transplant Recipients in CLINICAL PHARMACOKINETICS
  • 1993-06. Rational design of potent sialidase-based inhibitors of influenza virus replication in NATURE
  • 1983-05. Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 Å resolution in NATURE
  • 2008-06-04. Genetic Variation in Drug Transporters in Ethnic Populations in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • 2010-08. Safety of Oseltamivir in Pregnancy in DRUG SAFETY
  • 2009-05-26. Reducing the Burden of Influenza-Associated Complications with Antiviral Therapy in INFECTION
  • 2003-08-09. Pharmacokinetics of anti-influenza prodrug oseltamivir in children aged 1–5 years in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 2007-04-10. A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir in CELL RESEARCH
  • 1999-11. Oseltamivir in DRUGS
  • 2004-01. Oseltamivir Distributes to Influenza Virus Replication Sites in the Middle Ear and Sinuses in CLINICAL DRUG INVESTIGATION
  • 1999-11. Oseltamivir in DRUGS
  • 2003-09. Safety and Pharmacology of Oseltamivir in Clinical Use in DRUG SAFETY
  • 1998-04. Clinical Pharmacokinetics in the 21st Century in CLINICAL PHARMACOKINETICS
  • 2006-03-28. Avian influenza (H5N1): implications for intensive care in INTENSIVE CARE MEDICINE
  • 2007-04-16. Side effects of Tamiflu: clues from an Asian single nucleotide polymorphism in CELL RESEARCH
  • 1999-12. Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802 in CLINICAL PHARMACOKINETICS
  • 2009-09-22. Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)? in CELL RESEARCH
  • 2007-12. The war against influenza: discovery and development of sialidase inhibitors in NATURE REVIEWS DRUG DISCOVERY
  • 2001-03. Pharmacokinetics and Dosage Recommendations for an Oseltamivir Oral Suspension for the Treatment of Influenza in Children in PEDIATRIC DRUGS
  • 2003-12. Principles and Clinical Application of Assessing Alterations in Renal Elimination Pathways in CLINICAL PHARMACOKINETICS
  • 1983-05. Structure of the catalytic and antigenic sites in influenza virus neuraminidase in NATURE
  • 2008-12. Assessment of Neuropsychiatric Adverse Events in Influenza Patients Treated with Oseltamivir in DRUG SAFETY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/11534730-000000000-00000

    DOI

    http://dx.doi.org/10.2165/11534730-000000000-00000

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1003074611

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/20923248


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antiviral Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Area Under Curve", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Outbreaks", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Dose-Response Relationship, Drug", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Monitoring", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Influenza A Virus, H1N1 Subtype", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Influenza A Virus, H5N1 Subtype", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Influenza Vaccines", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Influenza, Human", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Oseltamivir", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pandemics", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Prodrugs", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "United States", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Widmer", 
            "givenName": "Nicolas", 
            "id": "sg:person.0615552455.00", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615552455.00"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Microbiology Institute, University Hospital Center and University of Lausanne, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Microbiology Institute, University Hospital Center and University of Lausanne, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Meylan", 
            "givenName": "Pascal", 
            "id": "sg:person.01336350503.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336350503.09"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Ivanyuk", 
            "givenName": "Anton", 
            "id": "sg:person.01371063010.43", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371063010.43"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Aouri", 
            "givenName": "Manel", 
            "id": "sg:person.01016132321.92", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016132321.92"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Decosterd", 
            "givenName": "Laurent A.", 
            "id": "sg:person.01344344533.08", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344344533.08"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland", 
              "id": "http://www.grid.ac/institutes/grid.9851.5", 
              "name": [
                "Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Buclin", 
            "givenName": "Thierry", 
            "id": "sg:person.01230116133.26", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230116133.26"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.2165/00003088-200948060-00006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046214298", 
              "https://doi.org/10.2165/00003088-200948060-00006"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/303035a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027570324", 
              "https://doi.org/10.1038/303035a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/303041a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026375653", 
              "https://doi.org/10.1038/303041a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/cr.2007.27", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050605496", 
              "https://doi.org/10.1038/cr.2007.27"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00228-003-0639-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018450868", 
              "https://doi.org/10.1007/s00228-003-0639-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/clpt.2008.98", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028984096", 
              "https://doi.org/10.1038/clpt.2008.98"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00002018-200326110-00004", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011612039", 
              "https://doi.org/10.2165/00002018-200326110-00004"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s15010-009-8241-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000068332", 
              "https://doi.org/10.1007/s15010-009-8241-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/cr.2009.111", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027540769", 
              "https://doi.org/10.1038/cr.2009.111"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/0002018-200831120-00006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002394351", 
              "https://doi.org/10.2165/0002018-200831120-00006"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/cr.2007.30", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000386788", 
              "https://doi.org/10.1038/cr.2007.30"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00128072-200103030-00005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004789142", 
              "https://doi.org/10.2165/00128072-200103030-00005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/11536370-000000000-00000", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018728544", 
              "https://doi.org/10.2165/11536370-000000000-00000"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00044011-200424010-00006", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042870971", 
              "https://doi.org/10.2165/00044011-200424010-00006"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00134-006-0148-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1047148965", 
              "https://doi.org/10.1007/s00134-006-0148-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-199958050-00007", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046190709", 
              "https://doi.org/10.2165/00003495-199958050-00007"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/363418a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031791476", 
              "https://doi.org/10.1038/363418a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd2400", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051391124", 
              "https://doi.org/10.1038/nrd2400"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/446358a", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009451725", 
              "https://doi.org/10.1038/446358a"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-199937060-00003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013722712", 
              "https://doi.org/10.2165/00003088-199937060-00003"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-199834040-00001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1001613980", 
              "https://doi.org/10.2165/00003088-199834040-00001"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003495-199958050-00009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021165751", 
              "https://doi.org/10.2165/00003495-199958050-00009"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00003088-200342140-00002", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027252871", 
              "https://doi.org/10.2165/00003088-200342140-00002"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2010-11", 
        "datePublishedReg": "2010-11-01", 
        "description": "Oseltamivir is the ester-type prodrug of the neuraminidase inhibitor oseltamivir carboxylate. It has been shown to be an effective treatment for both seasonal influenza and the recent pandemic 2009 A/H1N1 influenza, reducing both the duration and severity of the illness. It is also effective when used preventively. This review aims to describe the current knowledge of the pharmacokinetic and pharmacodynamic characteristics of this agent, and to address the issue of possible therapeutic drug monitoring.According to the currently available literature, the pharmacokinetics of oseltamivir carboxylate after oral administration of oseltamivir are characterized by mean \u00b1 SD bioavailability of 79 \u00b1 12%, apparent clearance of 25.3\u00b17.0L/h, an elimination half-life of 7.4\u00b12.5 hours and an apparent terminal volume of distribution of 267 \u00b1 122 L. A maximum plasma concentration of 342\u00b183 \u03bcg/L, a time to reach the maximum plasma concentration of 4.2 \u00b1 1.1 hours, a trough plasma concentration of 168\u00b132mg/L and an area under the plasma concentration-time curve from 0 to 24 hours of 6110 \u00b1 1330 mg \u00b7 h/L for a 75 mg twice-daily regimen were derived from literature data. The apparent clearance is highly correlated with renal function, hence the dosage needs to be adjusted in proportion to the glomerular filtration rate. Interpatient variability is moderate (28% in apparent clearance and 46% in the apparent central volume of distribution); there is no indication of significant erratic or limited absorption in given patient subgroups.The in vitro pharmacodynamics of oseltamivir carboxylate reveal wide variation in the concentration producing 50% inhibition of influenza A and B strains (range 0.17\u201344 \u03bcg/L). A formal correlation between systemic exposure to oseltamivir carboxylate and clinical antiviral activity or tolerance in influenza patients has not yet been demonstrated; thus no formal therapeutic or toxic range can be proposed.The pharmacokinetic parameters of oseltamivir carboxylate after oseltamivir administration (bioavailability, apparent clearance and the volume of distribution) are fairly predictable in healthy subjects, with little interpatient variability outside the effect of renal function in all patients and bodyweight in children. Thus oseltamivir carboxylate exposure can probably be controlled with sufficient accuracy by thorough dosage adjustment according to patient characteristics. However, there is a lack of clinical study data on naturally infected patients. In addition, the therapeutic margin of oseltamivir carboxylate is poorly defined. The usefulness of systematic therapeutic drug monitoring in patients therefore appears to be questionable; however, studies are still needed to extend the knowledge to particular subgroups of patients or dosage regimens.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/11534730-000000000-00000", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1085321", 
            "issn": [
              "0312-5963", 
              "1179-1926"
            ], 
            "name": "Clinical Pharmacokinetics", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "11", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "49"
          }
        ], 
        "keywords": [
          "maximum plasma concentration", 
          "oseltamivir carboxylate", 
          "therapeutic drug monitoring", 
          "plasma concentrations", 
          "renal function", 
          "apparent clearance", 
          "H1N1 influenza", 
          "interpatient variability", 
          "drug monitoring", 
          "neuraminidase inhibitor oseltamivir carboxylate", 
          "systematic therapeutic drug monitoring", 
          "plasma concentration-time curve", 
          "trough plasma concentrations", 
          "glomerular filtration rate", 
          "concentration-time curve", 
          "little interpatient variability", 
          "ester-type prodrug", 
          "clinical study data", 
          "SD bioavailability", 
          "oseltamivir administration", 
          "daily regimen", 
          "influenza patients", 
          "patient characteristics", 
          "dosage adjustment", 
          "systemic exposure", 
          "seasonal influenza", 
          "patient subgroups", 
          "pharmacodynamic characteristics", 
          "dosage regimens", 
          "filtration rate", 
          "oral administration", 
          "influenza A", 
          "therapeutic margin", 
          "avian H5N1", 
          "healthy subjects", 
          "effective treatment", 
          "pharmacokinetic parameters", 
          "patients", 
          "terminal volume", 
          "antiviral activity", 
          "toxic range", 
          "oseltamivir", 
          "B strains", 
          "influenza", 
          "particular subgroup", 
          "administration", 
          "available literature", 
          "clearance", 
          "current knowledge", 
          "study data", 
          "subgroups", 
          "hours", 
          "limited absorption", 
          "exposure", 
          "wide variation", 
          "regimen", 
          "regimens", 
          "pharmacodynamics", 
          "pharmacokinetics", 
          "illness", 
          "bodyweight", 
          "severity", 
          "prodrug", 
          "H5N1", 
          "treatment", 
          "children", 
          "inhibition", 
          "concentration", 
          "duration", 
          "indications", 
          "subjects", 
          "dosage", 
          "bioavailability", 
          "review", 
          "agents", 
          "proportion", 
          "monitoring", 
          "function", 
          "adjustment", 
          "data", 
          "activity", 
          "elimination", 
          "study", 
          "knowledge", 
          "rate", 
          "correlation", 
          "lack", 
          "usefulness", 
          "variability", 
          "effect", 
          "volume", 
          "tolerance", 
          "strains", 
          "characteristics", 
          "formal correlation", 
          "literature data", 
          "literature", 
          "addition", 
          "margin", 
          "time", 
          "curves", 
          "area", 
          "means", 
          "absorption", 
          "issues", 
          "variation", 
          "parameters", 
          "range", 
          "distribution", 
          "accuracy", 
          "Seasonal", 
          "carboxylate", 
          "sufficient accuracy"
        ], 
        "name": "Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza", 
        "pagination": "741-765", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1003074611"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/11534730-000000000-00000"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "20923248"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/11534730-000000000-00000", 
          "https://app.dimensions.ai/details/publication/pub.1003074611"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-11-24T20:54", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_510.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/11534730-000000000-00000"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/11534730-000000000-00000'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/11534730-000000000-00000'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/11534730-000000000-00000'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/11534730-000000000-00000'


     

    This table displays all metadata directly associated to this object as RDF triples.

    359 TRIPLES      21 PREDICATES      176 URIs      145 LITERALS      21 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/11534730-000000000-00000 schema:about N04a2c61dc18a4093bf7faae69b35551e
    2 N0b5592c59c4846bc9159ec577875e8ef
    3 N0cacea8153714d62b9bbefed52d37c64
    4 N169e08f4efb248d382a6282fe2281d3a
    5 N1eafc35cdbdf424ba0db942eff998b79
    6 N2ddad9f4f7f34b16b1e9581e0ae79f80
    7 N56d7044d00fd4ce1af76daf99024fe5c
    8 N606efa1e1ad440ce9f5067f05ea6be38
    9 N60fd17863fe54139865727c5da198706
    10 N67d43be17fe840b598883af9ea13d3cf
    11 N7d9bb4e4718e4fc4af1d74e1ab223ec9
    12 N8cb99e55f4ef41099031f8491d3d6908
    13 Nc2d399a87fd44c8d96b1b2cb89909fa9
    14 Nc844b49cd34a44d497e928a39f240451
    15 anzsrc-for:11
    16 anzsrc-for:1103
    17 schema:author Ne69303a73fee49ec9b2947abab575d5a
    18 schema:citation sg:pub.10.1007/s00134-006-0148-z
    19 sg:pub.10.1007/s00228-003-0639-6
    20 sg:pub.10.1007/s15010-009-8241-1
    21 sg:pub.10.1038/303035a0
    22 sg:pub.10.1038/303041a0
    23 sg:pub.10.1038/363418a0
    24 sg:pub.10.1038/446358a
    25 sg:pub.10.1038/clpt.2008.98
    26 sg:pub.10.1038/cr.2007.27
    27 sg:pub.10.1038/cr.2007.30
    28 sg:pub.10.1038/cr.2009.111
    29 sg:pub.10.1038/nrd2400
    30 sg:pub.10.2165/00002018-200326110-00004
    31 sg:pub.10.2165/00003088-199834040-00001
    32 sg:pub.10.2165/00003088-199937060-00003
    33 sg:pub.10.2165/00003088-200342140-00002
    34 sg:pub.10.2165/00003088-200948060-00006
    35 sg:pub.10.2165/00003495-199958050-00007
    36 sg:pub.10.2165/00003495-199958050-00009
    37 sg:pub.10.2165/0002018-200831120-00006
    38 sg:pub.10.2165/00044011-200424010-00006
    39 sg:pub.10.2165/00128072-200103030-00005
    40 sg:pub.10.2165/11536370-000000000-00000
    41 schema:datePublished 2010-11
    42 schema:datePublishedReg 2010-11-01
    43 schema:description Oseltamivir is the ester-type prodrug of the neuraminidase inhibitor oseltamivir carboxylate. It has been shown to be an effective treatment for both seasonal influenza and the recent pandemic 2009 A/H1N1 influenza, reducing both the duration and severity of the illness. It is also effective when used preventively. This review aims to describe the current knowledge of the pharmacokinetic and pharmacodynamic characteristics of this agent, and to address the issue of possible therapeutic drug monitoring.According to the currently available literature, the pharmacokinetics of oseltamivir carboxylate after oral administration of oseltamivir are characterized by mean ± SD bioavailability of 79 ± 12%, apparent clearance of 25.3±7.0L/h, an elimination half-life of 7.4±2.5 hours and an apparent terminal volume of distribution of 267 ± 122 L. A maximum plasma concentration of 342±83 μg/L, a time to reach the maximum plasma concentration of 4.2 ± 1.1 hours, a trough plasma concentration of 168±32mg/L and an area under the plasma concentration-time curve from 0 to 24 hours of 6110 ± 1330 mg · h/L for a 75 mg twice-daily regimen were derived from literature data. The apparent clearance is highly correlated with renal function, hence the dosage needs to be adjusted in proportion to the glomerular filtration rate. Interpatient variability is moderate (28% in apparent clearance and 46% in the apparent central volume of distribution); there is no indication of significant erratic or limited absorption in given patient subgroups.The in vitro pharmacodynamics of oseltamivir carboxylate reveal wide variation in the concentration producing 50% inhibition of influenza A and B strains (range 0.17–44 μg/L). A formal correlation between systemic exposure to oseltamivir carboxylate and clinical antiviral activity or tolerance in influenza patients has not yet been demonstrated; thus no formal therapeutic or toxic range can be proposed.The pharmacokinetic parameters of oseltamivir carboxylate after oseltamivir administration (bioavailability, apparent clearance and the volume of distribution) are fairly predictable in healthy subjects, with little interpatient variability outside the effect of renal function in all patients and bodyweight in children. Thus oseltamivir carboxylate exposure can probably be controlled with sufficient accuracy by thorough dosage adjustment according to patient characteristics. However, there is a lack of clinical study data on naturally infected patients. In addition, the therapeutic margin of oseltamivir carboxylate is poorly defined. The usefulness of systematic therapeutic drug monitoring in patients therefore appears to be questionable; however, studies are still needed to extend the knowledge to particular subgroups of patients or dosage regimens.
    44 schema:genre article
    45 schema:isAccessibleForFree false
    46 schema:isPartOf N2dbcd29a66a24d52ada07f5bc5d2d0ca
    47 Nb4527295f91946b99abec431526c460f
    48 sg:journal.1085321
    49 schema:keywords B strains
    50 H1N1 influenza
    51 H5N1
    52 SD bioavailability
    53 Seasonal
    54 absorption
    55 accuracy
    56 activity
    57 addition
    58 adjustment
    59 administration
    60 agents
    61 antiviral activity
    62 apparent clearance
    63 area
    64 available literature
    65 avian H5N1
    66 bioavailability
    67 bodyweight
    68 carboxylate
    69 characteristics
    70 children
    71 clearance
    72 clinical study data
    73 concentration
    74 concentration-time curve
    75 correlation
    76 current knowledge
    77 curves
    78 daily regimen
    79 data
    80 distribution
    81 dosage
    82 dosage adjustment
    83 dosage regimens
    84 drug monitoring
    85 duration
    86 effect
    87 effective treatment
    88 elimination
    89 ester-type prodrug
    90 exposure
    91 filtration rate
    92 formal correlation
    93 function
    94 glomerular filtration rate
    95 healthy subjects
    96 hours
    97 illness
    98 indications
    99 influenza
    100 influenza A
    101 influenza patients
    102 inhibition
    103 interpatient variability
    104 issues
    105 knowledge
    106 lack
    107 limited absorption
    108 literature
    109 literature data
    110 little interpatient variability
    111 margin
    112 maximum plasma concentration
    113 means
    114 monitoring
    115 neuraminidase inhibitor oseltamivir carboxylate
    116 oral administration
    117 oseltamivir
    118 oseltamivir administration
    119 oseltamivir carboxylate
    120 parameters
    121 particular subgroup
    122 patient characteristics
    123 patient subgroups
    124 patients
    125 pharmacodynamic characteristics
    126 pharmacodynamics
    127 pharmacokinetic parameters
    128 pharmacokinetics
    129 plasma concentration-time curve
    130 plasma concentrations
    131 prodrug
    132 proportion
    133 range
    134 rate
    135 regimen
    136 regimens
    137 renal function
    138 review
    139 seasonal influenza
    140 severity
    141 strains
    142 study
    143 study data
    144 subgroups
    145 subjects
    146 sufficient accuracy
    147 systematic therapeutic drug monitoring
    148 systemic exposure
    149 terminal volume
    150 therapeutic drug monitoring
    151 therapeutic margin
    152 time
    153 tolerance
    154 toxic range
    155 treatment
    156 trough plasma concentrations
    157 usefulness
    158 variability
    159 variation
    160 volume
    161 wide variation
    162 schema:name Oseltamivir in Seasonal, Avian H5N1 and Pandemic 2009 A/H1N1 Influenza
    163 schema:pagination 741-765
    164 schema:productId N1b9fe3cafdc94a9cae18144138e39b20
    165 N40f8d3a49c19469ba453310e84b20f4d
    166 Naf6bd11432884a48a96e9b0d1f100c8e
    167 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003074611
    168 https://doi.org/10.2165/11534730-000000000-00000
    169 schema:sdDatePublished 2022-11-24T20:54
    170 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    171 schema:sdPublisher N945e828df27d416fbb296e146cb125b5
    172 schema:url https://doi.org/10.2165/11534730-000000000-00000
    173 sgo:license sg:explorer/license/
    174 sgo:sdDataset articles
    175 rdf:type schema:ScholarlyArticle
    176 N04a2c61dc18a4093bf7faae69b35551e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    177 schema:name Disease Outbreaks
    178 rdf:type schema:DefinedTerm
    179 N0b5592c59c4846bc9159ec577875e8ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    180 schema:name Oseltamivir
    181 rdf:type schema:DefinedTerm
    182 N0cacea8153714d62b9bbefed52d37c64 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name United States
    184 rdf:type schema:DefinedTerm
    185 N169e08f4efb248d382a6282fe2281d3a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    186 schema:name Dose-Response Relationship, Drug
    187 rdf:type schema:DefinedTerm
    188 N1b9fe3cafdc94a9cae18144138e39b20 schema:name doi
    189 schema:value 10.2165/11534730-000000000-00000
    190 rdf:type schema:PropertyValue
    191 N1e2ad5b5f2a940a98105df3b93a04783 rdf:first sg:person.01336350503.09
    192 rdf:rest N62be855ea42d4be69f642841c5dd97f9
    193 N1eafc35cdbdf424ba0db942eff998b79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    194 schema:name Influenza A Virus, H5N1 Subtype
    195 rdf:type schema:DefinedTerm
    196 N2b9ff2a4ba70487eb9eb2dc7a8f46622 rdf:first sg:person.01344344533.08
    197 rdf:rest N774c17dca54243b8b4946b9edd863559
    198 N2dbcd29a66a24d52ada07f5bc5d2d0ca schema:volumeNumber 49
    199 rdf:type schema:PublicationVolume
    200 N2ddad9f4f7f34b16b1e9581e0ae79f80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    201 schema:name Antiviral Agents
    202 rdf:type schema:DefinedTerm
    203 N40f8d3a49c19469ba453310e84b20f4d schema:name dimensions_id
    204 schema:value pub.1003074611
    205 rdf:type schema:PropertyValue
    206 N56d7044d00fd4ce1af76daf99024fe5c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    207 schema:name Drug Monitoring
    208 rdf:type schema:DefinedTerm
    209 N606efa1e1ad440ce9f5067f05ea6be38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    210 schema:name Influenza, Human
    211 rdf:type schema:DefinedTerm
    212 N60fd17863fe54139865727c5da198706 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    213 schema:name Humans
    214 rdf:type schema:DefinedTerm
    215 N62be855ea42d4be69f642841c5dd97f9 rdf:first sg:person.01371063010.43
    216 rdf:rest N69b51b0cfeef444cb432c4308eb36687
    217 N67d43be17fe840b598883af9ea13d3cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    218 schema:name Pandemics
    219 rdf:type schema:DefinedTerm
    220 N69b51b0cfeef444cb432c4308eb36687 rdf:first sg:person.01016132321.92
    221 rdf:rest N2b9ff2a4ba70487eb9eb2dc7a8f46622
    222 N774c17dca54243b8b4946b9edd863559 rdf:first sg:person.01230116133.26
    223 rdf:rest rdf:nil
    224 N7d9bb4e4718e4fc4af1d74e1ab223ec9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    225 schema:name Influenza Vaccines
    226 rdf:type schema:DefinedTerm
    227 N8cb99e55f4ef41099031f8491d3d6908 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    228 schema:name Area Under Curve
    229 rdf:type schema:DefinedTerm
    230 N945e828df27d416fbb296e146cb125b5 schema:name Springer Nature - SN SciGraph project
    231 rdf:type schema:Organization
    232 Naf6bd11432884a48a96e9b0d1f100c8e schema:name pubmed_id
    233 schema:value 20923248
    234 rdf:type schema:PropertyValue
    235 Nb4527295f91946b99abec431526c460f schema:issueNumber 11
    236 rdf:type schema:PublicationIssue
    237 Nc2d399a87fd44c8d96b1b2cb89909fa9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    238 schema:name Prodrugs
    239 rdf:type schema:DefinedTerm
    240 Nc844b49cd34a44d497e928a39f240451 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    241 schema:name Influenza A Virus, H1N1 Subtype
    242 rdf:type schema:DefinedTerm
    243 Ne69303a73fee49ec9b2947abab575d5a rdf:first sg:person.0615552455.00
    244 rdf:rest N1e2ad5b5f2a940a98105df3b93a04783
    245 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    246 schema:name Medical and Health Sciences
    247 rdf:type schema:DefinedTerm
    248 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    249 schema:name Clinical Sciences
    250 rdf:type schema:DefinedTerm
    251 sg:journal.1085321 schema:issn 0312-5963
    252 1179-1926
    253 schema:name Clinical Pharmacokinetics
    254 schema:publisher Springer Nature
    255 rdf:type schema:Periodical
    256 sg:person.01016132321.92 schema:affiliation grid-institutes:grid.9851.5
    257 schema:familyName Aouri
    258 schema:givenName Manel
    259 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01016132321.92
    260 rdf:type schema:Person
    261 sg:person.01230116133.26 schema:affiliation grid-institutes:grid.9851.5
    262 schema:familyName Buclin
    263 schema:givenName Thierry
    264 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01230116133.26
    265 rdf:type schema:Person
    266 sg:person.01336350503.09 schema:affiliation grid-institutes:grid.9851.5
    267 schema:familyName Meylan
    268 schema:givenName Pascal
    269 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336350503.09
    270 rdf:type schema:Person
    271 sg:person.01344344533.08 schema:affiliation grid-institutes:grid.9851.5
    272 schema:familyName Decosterd
    273 schema:givenName Laurent A.
    274 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344344533.08
    275 rdf:type schema:Person
    276 sg:person.01371063010.43 schema:affiliation grid-institutes:grid.9851.5
    277 schema:familyName Ivanyuk
    278 schema:givenName Anton
    279 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01371063010.43
    280 rdf:type schema:Person
    281 sg:person.0615552455.00 schema:affiliation grid-institutes:grid.9851.5
    282 schema:familyName Widmer
    283 schema:givenName Nicolas
    284 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0615552455.00
    285 rdf:type schema:Person
    286 sg:pub.10.1007/s00134-006-0148-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1047148965
    287 https://doi.org/10.1007/s00134-006-0148-z
    288 rdf:type schema:CreativeWork
    289 sg:pub.10.1007/s00228-003-0639-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018450868
    290 https://doi.org/10.1007/s00228-003-0639-6
    291 rdf:type schema:CreativeWork
    292 sg:pub.10.1007/s15010-009-8241-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000068332
    293 https://doi.org/10.1007/s15010-009-8241-1
    294 rdf:type schema:CreativeWork
    295 sg:pub.10.1038/303035a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027570324
    296 https://doi.org/10.1038/303035a0
    297 rdf:type schema:CreativeWork
    298 sg:pub.10.1038/303041a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026375653
    299 https://doi.org/10.1038/303041a0
    300 rdf:type schema:CreativeWork
    301 sg:pub.10.1038/363418a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031791476
    302 https://doi.org/10.1038/363418a0
    303 rdf:type schema:CreativeWork
    304 sg:pub.10.1038/446358a schema:sameAs https://app.dimensions.ai/details/publication/pub.1009451725
    305 https://doi.org/10.1038/446358a
    306 rdf:type schema:CreativeWork
    307 sg:pub.10.1038/clpt.2008.98 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028984096
    308 https://doi.org/10.1038/clpt.2008.98
    309 rdf:type schema:CreativeWork
    310 sg:pub.10.1038/cr.2007.27 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050605496
    311 https://doi.org/10.1038/cr.2007.27
    312 rdf:type schema:CreativeWork
    313 sg:pub.10.1038/cr.2007.30 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000386788
    314 https://doi.org/10.1038/cr.2007.30
    315 rdf:type schema:CreativeWork
    316 sg:pub.10.1038/cr.2009.111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027540769
    317 https://doi.org/10.1038/cr.2009.111
    318 rdf:type schema:CreativeWork
    319 sg:pub.10.1038/nrd2400 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051391124
    320 https://doi.org/10.1038/nrd2400
    321 rdf:type schema:CreativeWork
    322 sg:pub.10.2165/00002018-200326110-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011612039
    323 https://doi.org/10.2165/00002018-200326110-00004
    324 rdf:type schema:CreativeWork
    325 sg:pub.10.2165/00003088-199834040-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001613980
    326 https://doi.org/10.2165/00003088-199834040-00001
    327 rdf:type schema:CreativeWork
    328 sg:pub.10.2165/00003088-199937060-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013722712
    329 https://doi.org/10.2165/00003088-199937060-00003
    330 rdf:type schema:CreativeWork
    331 sg:pub.10.2165/00003088-200342140-00002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027252871
    332 https://doi.org/10.2165/00003088-200342140-00002
    333 rdf:type schema:CreativeWork
    334 sg:pub.10.2165/00003088-200948060-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046214298
    335 https://doi.org/10.2165/00003088-200948060-00006
    336 rdf:type schema:CreativeWork
    337 sg:pub.10.2165/00003495-199958050-00007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046190709
    338 https://doi.org/10.2165/00003495-199958050-00007
    339 rdf:type schema:CreativeWork
    340 sg:pub.10.2165/00003495-199958050-00009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021165751
    341 https://doi.org/10.2165/00003495-199958050-00009
    342 rdf:type schema:CreativeWork
    343 sg:pub.10.2165/0002018-200831120-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002394351
    344 https://doi.org/10.2165/0002018-200831120-00006
    345 rdf:type schema:CreativeWork
    346 sg:pub.10.2165/00044011-200424010-00006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042870971
    347 https://doi.org/10.2165/00044011-200424010-00006
    348 rdf:type schema:CreativeWork
    349 sg:pub.10.2165/00128072-200103030-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004789142
    350 https://doi.org/10.2165/00128072-200103030-00005
    351 rdf:type schema:CreativeWork
    352 sg:pub.10.2165/11536370-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018728544
    353 https://doi.org/10.2165/11536370-000000000-00000
    354 rdf:type schema:CreativeWork
    355 grid-institutes:grid.9851.5 schema:alternateName Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    356 Microbiology Institute, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    357 schema:name Division of Clinical Pharmacology and Toxicology, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    358 Microbiology Institute, University Hospital Center and University of Lausanne, Lausanne, Switzerland
    359 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...